Effect of rosuvastatin and eicosapentaenoic acid on neoatherosclerosis: the LINK-IT Trial
Kuroda K, Otake H, Shinohara M, Kuroda M, Tsuda S, Toba T, Nagano Y, Toh R, Ishida T, Shinke T, Hirata KI
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 19 citations
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- Government
- Japan Society for the Promotion of Science
- Grants
- Japan Society for the Promotion of Science (18K08072); Japan Society for the Promotion of Science (17K09579); Japan Society for the Promotion of Science (17K09553)
Based on 1 listed funder(s).
Publication
- Published
- 2019-12-01 · EuroIntervention · vol. 15 · issue 12 · pp. e1099–e1106
- Publisher
- European Association of Percutaneous Cardiovascular Interventions
- Cited
- 22 citations · more than 89% of similar papers · 2.5× the field average
- References
- 13 works
- Access
- Paywalled
- Research areas
- Lipoproteins and Cardiovascular Health · Cancer, Lipids, and Metabolism · Liver Disease Diagnosis and Treatment
- Keywords
- Rosuvastatin, Medicine, Eicosapentaenoic acid, Internal medicine, Rosuvastatin Calcium, Gastroenterology, Urology, Fatty acid, Polyunsaturated fatty acid, Biochemistry
- MeSH
- humans, eicosapentaenoic acid, anticholesteremic agents, hydroxymethylglutaryl-coa reductase inhibitors, tomography, optical coherence, treatment outcome, prospective studies, dose-response relationship, drug, atherosclerosis, rosuvastatin calcium
11 authors
From JP
- Koji KurodaKobe University
- Hiromasa Otake
- Masakazu Shinohara
- Masaru Kuroda
- Shigeyasu Tsuda
- Takayoshi Toba
Abstract
Aims
We aimed to assess the effect of 10 mg/day of rosuvastatin plus eicosapentaenoic acid (EPA) versus 2.5 mg/day of rosuvastatin on the extent of neoatherosclerosis using optical coherence tomography (OCT).
Methods and results
We randomly assigned 50 patients with non-obstructive neoatherosclerotic plaques detected on OCT to receive either rosuvastatin 10 mg/day and EPA 1,800 mg/day (intensive therapy group) or rosuvastatin 2.5 mg (standard therapy group). Follow-up OCT was performed one year later to evaluate serial changes in neoatherosclerosis. The serum low-density lipoprotein cholesterol (LDL-C) level decreased significantly from baseline to 12-month follow-up in the intensive therapy group (89 mg/dL to 70 mg/dL; p<0.001), while no change occurred in the standard therapy group. Lipid index change and percent changes in macrophage grade were significantly lower in the intensive therapy group than in the standard therapy group (-53.6 vs 310.1, p=0.001; -37.0% vs 35.3%, p<0.001; respectively). Percent changes in lipid index and macrophage grade were positively correlated with the changes in serum LDL-C and C-reactive protein levels, and negatively correlated with the change in serum EPA/arachidonic acid and 18-hydroxyeicosapentaenoic acid (EPA bioactive metabolite) level.
Conclusions
Compared with rosuvastatin 2.5 mg/day, rosuvastatin 10 mg/day and EPA 1,800 mg/day significantly stabilised non-obstructive neoatherosclerotic plaques.
Clinical trial registration
UMIN ID: UMIN000012576. https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014711.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.